Market Cap 8.82M
Revenue (ttm) 0.00
Net Income (ttm) -16.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,500
Avg Vol 20,678
Day's Range N/A - N/A
Shares Out 834,000.00
Stochastic %K 63%
Beta 1.50
Analysts Strong Buy
Price Target $10.00

Company Profile

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and t...

Industry: Biotechnology
Sector: Healthcare
Phone: 857-837-3099
Address:
6 Liberty Square, Suite 2382, Boston, United States
phantomtrader75
phantomtrader75 Oct. 4 at 8:41 PM
$RNAZ I reported them to SEC and NASDAQ just right before the last split (as well as reporting all affiliated parties) that were complicit. They received a warning and they are on a watch list for purported illegal activities related to improper dilution. That’s why this has been dead in water - they actually have to obey the rules as they are now under heavy scrutiny.
0 · Reply
mbr60
mbr60 Oct. 3 at 9:35 PM
$RNAZ : 🔹 Perspective With the company recently amending its intellectual property agreement with Mass General, the question arises: Could this be a prelude to a strategic partnership in the near future? ✨ Especially since management had previously promised a clinical update at the beginning of September but has yet to deliver it — which may suggest that a bigger step is being prepared behind the scenes. 📌 In the biotech world, adjustments to IP agreements often precede major announcements such as partnerships or strategic funding, making the upcoming period potentially pivotal for the company and its share price.🔥🔥🔥
3 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:40 PM
$RNAZ $XAGE $MLEC $CDIO Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 12:48 AM
0 · Reply
rock_it_stocks
rock_it_stocks Oct. 2 at 9:22 PM
$RNAZ A short read of a venture capitalist's take on recent acquisitions of companies with products in Phase 1 (just food for thought): https://www.linkedin.com/posts/johnathanmatlock_why-would-pharma-pay-billions-for-unproven-activity-7374790889254318080-e-Lt .
1 · Reply
BabyDoll1
BabyDoll1 Oct. 2 at 7:13 PM
$RNAZ Have not been here in a while.. have they released any data? Nothing on their “investors” page..
2 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:42 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $CNEY $BON $RNAZ $XAGE
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 2 at 2:15 PM
$RNAZ Current Stock Price: $11.00 No options data available.
1 · Reply
Vedran1
Vedran1 Oct. 2 at 4:27 AM
$RNAZ Since the Oncologist / Hematologist presents the poster this is important step forward into medical community about Transcode's basic science research and its recent clinical achievements. An abstract in a form of poster presentation usually preeceds a complete scientific publication in a peer reviewed journal - sometime for a few months, sometime for a year or two. I see this event as a natural progression of Transcodes research and work. This is a slow scientific and clinical process of building a strong base from which we will move on to where we hope to be. It is hard to cut corners here, unless there are extraordinary clinical results early on. https://faculty.mdanderson.org/profiles/siqing_fu.html
1 · Reply
dishenghk
dishenghk Oct. 2 at 3:01 AM
$RNAZ https://oncologypro.esmo.org/content/search?searchText=Phase%201/2%20Clinical%20Study%20of%20a%20First-in-Class%20Antisense%20Oligonucleotide%20(TTX-MC138)%20Therapeutic%20against%20Advanced%20Solid%20Tumors%20of%20Multiple%20Tissue%20Origins From the information on the esmo official website, I found that this might be a brief meeting, not just a poster. "Poster session" vs "Poster Display"
0 · Reply
Latest News on RNAZ
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 2, 2025, 4:10 PM EDT - 5 months ago

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split


TransCode Therapeutics Open Letter to Shareholders

May 13, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Open Letter to Shareholders


TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Jan 11, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split


TransCode Therapeutics Withdraws Public Offering

Oct 30, 2023, 4:33 PM EDT - 2 years ago

TransCode Therapeutics Withdraws Public Offering


phantomtrader75
phantomtrader75 Oct. 4 at 8:41 PM
$RNAZ I reported them to SEC and NASDAQ just right before the last split (as well as reporting all affiliated parties) that were complicit. They received a warning and they are on a watch list for purported illegal activities related to improper dilution. That’s why this has been dead in water - they actually have to obey the rules as they are now under heavy scrutiny.
0 · Reply
mbr60
mbr60 Oct. 3 at 9:35 PM
$RNAZ : 🔹 Perspective With the company recently amending its intellectual property agreement with Mass General, the question arises: Could this be a prelude to a strategic partnership in the near future? ✨ Especially since management had previously promised a clinical update at the beginning of September but has yet to deliver it — which may suggest that a bigger step is being prepared behind the scenes. 📌 In the biotech world, adjustments to IP agreements often precede major announcements such as partnerships or strategic funding, making the upcoming period potentially pivotal for the company and its share price.🔥🔥🔥
3 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:40 PM
$RNAZ $XAGE $MLEC $CDIO Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 12:48 AM
0 · Reply
rock_it_stocks
rock_it_stocks Oct. 2 at 9:22 PM
$RNAZ A short read of a venture capitalist's take on recent acquisitions of companies with products in Phase 1 (just food for thought): https://www.linkedin.com/posts/johnathanmatlock_why-would-pharma-pay-billions-for-unproven-activity-7374790889254318080-e-Lt .
1 · Reply
BabyDoll1
BabyDoll1 Oct. 2 at 7:13 PM
$RNAZ Have not been here in a while.. have they released any data? Nothing on their “investors” page..
2 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:42 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $CNEY $BON $RNAZ $XAGE
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 2 at 2:15 PM
$RNAZ Current Stock Price: $11.00 No options data available.
1 · Reply
Vedran1
Vedran1 Oct. 2 at 4:27 AM
$RNAZ Since the Oncologist / Hematologist presents the poster this is important step forward into medical community about Transcode's basic science research and its recent clinical achievements. An abstract in a form of poster presentation usually preeceds a complete scientific publication in a peer reviewed journal - sometime for a few months, sometime for a year or two. I see this event as a natural progression of Transcodes research and work. This is a slow scientific and clinical process of building a strong base from which we will move on to where we hope to be. It is hard to cut corners here, unless there are extraordinary clinical results early on. https://faculty.mdanderson.org/profiles/siqing_fu.html
1 · Reply
dishenghk
dishenghk Oct. 2 at 3:01 AM
$RNAZ https://oncologypro.esmo.org/content/search?searchText=Phase%201/2%20Clinical%20Study%20of%20a%20First-in-Class%20Antisense%20Oligonucleotide%20(TTX-MC138)%20Therapeutic%20against%20Advanced%20Solid%20Tumors%20of%20Multiple%20Tissue%20Origins From the information on the esmo official website, I found that this might be a brief meeting, not just a poster. "Poster session" vs "Poster Display"
0 · Reply
wazd
wazd Oct. 1 at 11:02 PM
$RNAZ do not waste your money on this. They will take your money. You will make more money buying weekly dividend stocks than this. Read previous posts…😎
1 · Reply
rock_it_stocks
rock_it_stocks Oct. 1 at 10:21 PM
$RNAZ Transcode to attend the ESMO 2025! Officially! https://ir.transcodetherapeutics.com/events#future
2 · Reply
Scrubinski
Scrubinski Oct. 1 at 1:13 PM
$RNAZ maybe us long investors that have gotten shelled on this stock anyway could pool together $5000 to put TT in a booth at an upcoming conference with some decent handouts and signage. Then TT just has to show up. Might be a worth while investment.
1 · Reply
ioiioiioiioi
ioiioiioiioi Oct. 1 at 5:37 AM
$RNAZ🚨 Found it! $RNAZ core pipeline TTX-MC138 abstract confirmed ✅ 983P: Phase I/II clinical study of a first-in-class antisense oligonucleotide (TTX-MC138) therapeutic against advanced solid tumors Presenter: Siqing Fu, M.D., Ph.D. @ ESMO 2025 (Berlin) Looks like there really will be a presentation. Until then, we just have to wait..! #RNAZ #ESMO2025 #Biotech #GBM https://www.mdanderson.org/research/research-resources/conferences-seminars/md-anderson-at-esmo/esmo-program.html?utm_source=chatgpt.com
2 · Reply
Scrubinski
Scrubinski Oct. 1 at 3:12 AM
$RNAZ I Have heard a few people talk about the ESMO conference in Berlin starting October 17. The timing and venue seems right for an announcement, but I can't find any evidence of TT planning to be there. This is the program https://dam.esmo.org/image/upload/v1758713047/ESMO-Congress-2025-Programme-Book_zjgwfc.pdf don't see anything. Nothing in the booth listing either. Maybe a poster? but usually a poster is just a trifold sitting on table surrounded by hundreds of other posters that may or may not have someone standing there. I guess it's better than nothing, but hard to get much interest in the poster room. Does anybody know anything different?
2 · Reply
soonwee640
soonwee640 Sep. 30 at 8:55 AM
$RNAZ today is the day if the CEO wants to keep his promise. I hope the cohort 1 continue demonstrate stable disease, and other cohorts show no disease progression. Then this is huge for this human trial because metastatic cancer basically in stage IV, survival time is short.
2 · Reply
TradingBeasts
TradingBeasts Sep. 29 at 6:42 PM
$RNAZ 15 soon
0 · Reply
rock_it_stocks
rock_it_stocks Sep. 29 at 5:21 PM
$RNAZ An $8 Billion buyout would be more than $4,000 per share for RNAZ, but that would require our board and management to start thinking and acting like shareholders! As of last reporting, our Board owns a total of 3 shares of common stock between 4 members, so what are the chances that they even care?
1 · Reply
Scrubinski
Scrubinski Sep. 29 at 5:14 PM
$RNAZ I promise to stop complaining if we are acquired for 300 a
0 · Reply
Zeusgodmd
Zeusgodmd Sep. 29 at 4:49 PM
$RNAZ maybe to avoid lawsuits we sell over 300$ per share hopefully our board keeps that in mind
0 · Reply
Vedran1
Vedran1 Sep. 29 at 2:53 PM
$RNAZ MRUS Fair acquisition price? https://www.businesswire.com/news/home/20250929898507/en/MRUS-Stock-Alert-Halper-Sadeh-LLC-Is-Investigating-Whether-the-Sale-of-Merus-N.V.-Is-Fair-to-Shareholders
0 · Reply
Vedran1
Vedran1 Sep. 29 at 2:50 PM
$RNAZ MERUS https://finance.yahoo.com/news/genmab-makes-8-billion-bet-141502866.html
0 · Reply